No Data
No Data
Lake Street Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $4
Lake Street analyst Thomas Flaten maintains $Personalis(PSNL.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of 38.1% and a tota
Analysts Offer Insights on Healthcare Companies: Personalis (PSNL) and G1 Therapeutics (GTHX)
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that two podium presentations and multiple posters featuring data for the company's NeXT Personal whole
Express News | Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
4 Analysts Have This To Say About Personalis
Personalis (NASDAQ:PSNL) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.Summarizing their recent assessments, the table below illustra
Tivic Health, RAPT Therapeutics, Notable Labs Among Healthcare Movers
No Data